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Research
AbstrACt
Objectives Investigate the acceptability of financial 
incentives for initiating a medically supervised 
benzodiazepine discontinuation programme among 
people with long-term benzodiazepine use and to 
identify programme features that influence willingness to 
participate.
Methods We conducted a discrete choice experiment in 
which we presented a variety of incentive-based programs 
to a sample of older adults with long-term benzodiazepine 
use identified using the outpatient electronic health 
record of a university-owned health system. We studied 
four programme variables: incentive amount for initiating 
the programme, incentive amount for successful 
benzodiazepine discontinuation, lottery versus certain 
payment and whether partial payment was given for 
dose reduction. Respondents reported their willingness to 
participate in the programmes and additional information 
was collected on demographics, history of use and anxiety 
symptoms.
results The overall response rate was 28.4%. Among the 
126 respondents, all four programme variables influenced 
stated preferences. Respondents strongly preferred 
guaranteed cash-based incentives as opposed to a lottery, 
and the dollar amount of both the starting and conditional 
incentives had a substantial impact on choice. Willingness 
to participate increased with the amount of conditional 
incentive. Programme participation also varied by gender, 
duration of use and income.
Conclusions Participation in an incentive-based 
benzodiazepine discontinuation programme might be 
relatively low, but is modifiable by programme variables 
including incentive amounts. These results will be helpful 
to inform the design of future trials of benzodiazepine 
discontinuation programmes. Further research is needed 
to assess the financial viability and potential cost-
effectiveness of such economic incentives.
IntrOduCtIOn
Benzodiazepines are frequently used to treat 
insomnia and anxiety disorders. In 2013, 
8.6% of Americans age 65 or above filled 
one or more benzodiazepine prescription.1 
While short-term use for panic disorder 
and insomnia are supported by some clin-
ical practice guidelines,2–4 long-term use 
is associated with serious risks, including 
overdose,1 misuse and use disorder,5 falls,6 
motor vehicle crashes,7 cognitive impair-
ment8 and dementia,9 particularly in older 
adults. Despite known risks associated with 
long-term use, discontinuing therapy with 
benzodiazepines can be very difficult because 
of physiological dependence as well as the 
potential for return of the symptoms that 
prompted benzodiazepine initiation.5 While 
withdrawal symptoms can be mitigated in part 
by a slow taper,10 many patients are resistant 
to initiation of the taper.11 Strategies such as 
providing patient education about the risks 
of benzodiazepine use have proven only 
modestly effective in encouraging discontin-
uation of therapy.12
In this context, giving people mone-
tary incentives conditional on achieving 
strengths and limitations of this study
 ► This study is the first to provide evidence on 
the acceptability of financial incentives for 
benzodiazepine discontinuation in older adults with 
a history of long-term benzodiazepine use.
 ► It provides insights into the preferences of this group 
of patients and will be helpful to inform the design 
of future trials of benzodiazepine discontinuation 
programmes.
 ► Our findings are limited by the relatively small 
number of participants and the focus on one study 
site.
 ► As we are using a stated preferences method, it is 
not clear whether patients would make the exact 
same choices when faced with the real-life decision.
group.bmj.com on October 16, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
2 Marti J, et al. BMJ Open 2017;7:e016229. doi:10.1136/bmjopen-2017-016229
Open Access 
reduction in use and discontinuation might be a useful 
approach. Standard economic theory suggests that giving 
people monetary incentives conditional on achieving 
a specific health-related goal can make the net benefits 
of behavioural change positive, immediate and more 
tangible for some individuals, and therefore increase the 
likelihood of seeing the target population adopt healthier 
behaviours.13 While this type of strategy is increasingly 
used and has been shown effective in several contexts,14–19 
no studies have explored the use of incentives in benzo-
diazepine use. Besides setting a monetary value that 
rewards a well-defined outcome, incentive design entails 
a careful consideration of a variety of features, especially 
in the case of behaviours involving repeated choices 
whose long-term consequences are likely to be under-
weighted in the decision-making process and can lead to 
persistent unhealthy habits. Characteristics of payments 
such as their frequency (regular versus one-off),20 
certainty (guaranteed payments versus lotteries),21 or 
their nature (cash versus vouchers), must be considered 
as they can influence take-up and success. Also, individ-
uals often exhibit decision-making biases such as loss 
aversion, present bias22 or the overweighting of small 
probabilities and previous work has shown that financial 
incentives designed around these biases are particularly 
effective in influencing behaviours.23 However, relatively 
little is known about the influence of incentive design on 
the willingness to participate in incentive-based programs 
and how to adapt the design to different populations/
behaviours to maximise take-up, especially in the case of 
older adults. Previous work in this population group has 
shown that even small incentives are likely to increase 
stated uptake of a physical activity programme and that 
cash incentives were preferred over vouchers.24 A recent 
UK study on acceptability of financial incentives targeted 
a range of behaviours showed that lottery-based incen-
tives were not deemed acceptable and that older people 
preferred programmes with no incentives.25 Identifying 
effective incentives becomes even more challenging 
when considering compulsive and potentially harmful 
behaviours that may be perceived as acceptable and safe 
such as the use of physician-prescribed drugs in general 
and benzodiazepine use in particular. Thus, there is a 
clear gap in knowledge about optimal incentive struc-
ture to present to older individuals to induce programme 
participation for healthy behavioural change. This study 
presents a unique opportunity to narrow this gap by 
focusing on patients with long-term prescription benzo-
diazepine use.
In this study, we used a discrete choice experiment 
(DCE) to investigate the acceptability of financial incen-
tives for initiating a medically supervised benzodiazepine 
discontinuation programme among long-term benzodi-
azepine users and to identify programme features that 
influence the willingness to participate. More specifi-
cally, we randomly presented a variety of incentive-based 
programs that differed according to a set of key features 
(eg, incentive amount, lottery versus certain payment) 
to a sample of older adults (age 50+ years) with long-
term benzodiazepine use. We then asked respondents to 
report their willingness to participate in the programmes 
and collected additional information on demographics, 
history of use and anxiety symptoms. We used discrete 
choice modelling to investigate the trade-offs that individ-
uals make between programme features as well as patient 
factors that affect willingness to participate.
MethOds
data collection
We identified potential subjects from the patient popula-
tion of the primary care and behavioural health outpatient 
practices of a university-owned health system. Eligible 
participants were aged 50 or older, with an anxiety diag-
nosis at any point as an outpatient or with anxiety listed 
on their active problem list within the electronic health 
record. Additionally, eligible participants must have had 
at least three benzodiazepine prescription orders in the 
previous 12 months, with the most recent prescription 
within 90 days of our initial screening for study partic-
ipants. Those with a history of a seizure disorder were 
excluded. Before contacting any participants, we reached 
out to each provider to give them the opportunity to 
opt-out any of their patients who they did not wish to 
participate in the study.
We contacted the remaining eligible participants over 
phone from May 2015 to August 2015. Contacted indi-
viduals who were no longer taking their benzodiazepine 
medication(s) were excluded as ineligible. Research staff 
obtained verbal consent over phone and subsequently 
randomised each participant to either version A or B of 
the study questionnaire (see Design of the choice exper-
iment section). Stamped and addressed envelopes were 
provided with the questionnaires for participants to easily 
return the surveys. On sending back the survey, all partic-
ipants were mailed a retail gift card worth US$20. The 
study was considered exempt from institutional review 
board oversight under exemption category 2 (ie, research 
involving the use of educational tests (cognitive, diag-
nostic, aptitude, achievement), survey procedures, inter-
view procedures or observation of public behaviour, and 
was deemed exempt by the University of Pennsylvania 
Institutional Review Board (protocol 820106) as (1) no 
information obtained is recorded in such a manner that 
human subjects can be identified, directly or through 
identifiers linked to the subjects and (2) no disclosure 
of the human subjects’ responses outside the research 
could reasonably place the subjects at risk of criminal 
or civil liability or be damaging to the subjects’ finan-
cial standing, employability or reputation). All survey 
responses were securely stored and all identifying infor-
mation was destroyed once the surveys were returned.
design of the choice experiment
DCEs have been used extensively to value goods and 
services for which there is no formal market or only 
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incomplete markets.26 In health and healthcare, these 
techniques have been applied to address a wide variety of 
research questions including the elicitation of patients’ 
preferences, the valuation of health outcomes and 
the trade-offs between health and non-health benefits 
of specific.26–28 Importantly, recent studies have used 
DCEs to investigate the design of financial incentive 
programmes.24 29–31 DCEs rely on random use theory and 
are based on the assumption that the value of goods or 
services is best described by the sum of its attributes (or 
characteristics) and that people’s choices are driven by 
the relative value of these characteristics. By presenting 
respondents with a series of choices between alternatives 
and by experimentally varying the characteristics of these 
alternatives, one is able to assess the trade-offs respon-
dents make between product/service characteristics and 
to measure their influence on choices. A DCE consists of 
several interdependent steps: defining the attributes and 
their levels, experimental and survey design, data collec-
tion and statistical modelling.26
We developed an initial list of potential attributes and 
levels of the tapering programme via a review of the liter-
ature on the design of financial incentives for behavioural 
change.32 We then refined this list in a series of team meet-
ings and through analysis of pilot data. In the final survey, 
we described hypothetical tapering programmes using four 
characteristics: cash reward to start the programme, the 
incentive amount received conditional on successful discon-
tinuation, whether the conditional incentive was given 
in the form of a certain cash payment or via a lottery and 
whether unsuccessful participants would still be rewarded 
for only cutting their use by half. These attributes and 
their respective levels are presented in table 1. The next 
step consisted of combining attributes to form choice sets 
used to reveal patients’ preferences. Because it would be 
infeasible to show respondents all possible combinations of 
attributes and levels (in our case, this would mean 42×22= 
64 possible combinations), we generated a fractional facto-
rial design using the N-gene software to obtain a reasonable 
number of choice sets (ie, 12) that is sufficient to estimate 
Table 1 Attributes and levels
Attributes Levels
Levels used for the ‘opt-
out’ option
Cash reward to start the programme (take-up) US$0, US$10, US$20, US$50 US$0
Incentive received conditional on successful 
discontinuation
US$200, US$400, US$600, US$1500 US$0
Half of the incentive received if use is cut in half Yes, No No
Incentive format Certain cash amount, lottery with a 1 
in 10 chance of winning
Certain cash amount
Figure 1 Example of choice question.
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the main effects of interest. We then divided the 12 choice 
sets into two blocks of 6 choice sets to reduce respondent 
fatigue, giving rise to two versions of the questionnaire (ie, 
A and B). While the number of choice sets was not found 
to be detrimental to DCE data quality,33 we had concerns 
that this could be an issue in older adults. In each choice 
set, respondents were asked (1) to choose their preferred 
tapering programme and (2) to state whether or not they 
would enrol if such a programme were available to them. 
As a simple validity check, we also asked respondents if they 
wanted to be contacted if a similar programme started and 
gave them the opportunity to provide their contact infor-
mation. An example of choice set is displayed in figure 1. 
We also collected information on demographics (ie, age, 
gender, education, income and household size), history of 
benzodiazepine use and current level of anxiety (measured 
using the Generalized Anxiety Disorder 7-Item (GAD-7) 
scale).34
statistical modelling
We started by describing our patient population and 
respondents’ choice patterns. We then estimated simple 
conditional logit models to assess the trade-offs made by 
individuals between the various programme characteristics, 
that is, to assess the relative importance of these characteris-
tics when making choices. We jointly modeled programme 
choice and take-up by including an alternative-specific 
constant (ASC) for the opt-out option. Due to the limita-
tion of the conditional logit model, which assumes homo-
geneous preferences in the population, we then estimated 
more flexible latent class logit models that identify a set 
of unobserved ‘classes’ or groups of individuals based on 
observed choice patterns. Separate parameter vectors (and 
variances) are estimated for each class, which allows for pref-
erence heterogeneity across the classes.35–38 Our preferred 
model, based on the Akaike Information Criteria, included 
two classes. A feature of the latent class model is that, while 
we cannot directly observe a respondent’s class member-
ship, we can model the likelihood of class membership as 
a function of individual characteristics to understand the 
composition of population classes. We complemented our 
analyses by predicting programme take-up among survey 
respondents for a range of incentive amounts for successful 
Figure 2 Sample flow chart.
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discontinuation. This was done by calculating the choice 
probabilities of each option, including the opt-out, using 
the latent class model. All analyses were performed using 
Stata 12. 
results
We identified 1108 potentially eligible participants. Of 
those, we could not reach 567 (reasons included being 
opted out by provider, invalid phone number, and not 
answering the phone after three attempts), 245 refused 
to participate and 37 were ineligible as they were no 
longer taking benzodiazepines (figure 2). We mailed the 
survey to the 285 remaining individuals and 143 returned 
their survey, giving rise to a 28.4% overall response rate 
(143÷(1108−567−37)) and a 50.2% response rate to the 
mailed survey among those who provided consent, which 
is in line with other DCE studies in health using postal 
surveys.39 We further excluded 17 respondents due to 
incomplete responses to the choice questions. Therefore, 
126 respondents provided complete and usable survey 
responses.
The majority of respondents were women (62%) and 
the average age of respondents was 63 years old (table 2). 
On average, respondents have been taking benzodiaze-
pines for 10 years, with history of use ranging from 1 to 
50 years. The majority of people took benzodiazepines 
daily or almost daily; only 19% took benzodiazepines 
once per week or less. Interestingly, 45% of respondents 
had previously tried to stop taking benzodiazepines. Most 
respondents (63%) had only minimal or mild anxiety as 
measured by the GAD-7 scale.
As an initial investigation of respondents’ preferences, 
we summarised their general choice patterns. As explained 
above and shown in figure 1, respondents were first asked 
to choose their preferred programme and then asked to 
state their willingness to enrol if such a programme were 
available. Responses to this second questions provided 
insight into the general willingness to enrol in incen-
tive programme in this population. Results showed that 
about 50% of respondents always (ie, in all six choice 
sets presented) answered ‘yes’ to the question ‘Would 
you enrol in the programme you picked above if you had 
the opportunity?’ Conversely about 30% of respondents 
always answered ‘no’ to that question. On average, the 
proportion of ‘yes’ responses across all respondents and 
choice sets was 67%, which reflects a fairly high potential 
enrolment rate among survey respondents. Interestingly, 
57% of respondents who answered ‘yes’ to the question 
‘Would you enrol in the programme you picked above 
if you had the opportunity?’ at least once expressed an 
interest in being contacted if such programme started, 
and shared their contact information.
The results from the conditional logit models shown 
in table 3 suggest that all studied attributes had an influ-
ence on choices. More precisely, as we would expect, the 
higher the monetary amount for both incentives (start 
and completion), the higher the probability the respon-
dent would choose that programme. We also observed 
that respondents tended to favour programmes that 
offer a reward even if complete discontinuation was not 
achieved. Finally, respondents in our sample were more 
likely to choose a programme that offers a cash reward 
rather than a lottery with equal expected value. While we 
did not include any choice set aimed at testing respon-
dents’ rationality, we formally investigated attribute 
dominance (ie, whether for some respondents, choices 
were driven by a single attribute).40 We identified three 
respondents who systematically chose the programme 
with the highest incentive, but have decided not to 
Table 2 Respondent characteristics (n=126)
Variables Mean (IQR)
Demographic characteristics
  Age 63.4 (57–69)
  Male 38%
  Education: high school or less 27%
  Income: less than US$25 000/year 14%
Use of BZD
  No of years of use 9.8 (4–15)
Frequency of use
  Once per week or less 19%
  1–3 times per week 18%
  Almost every day 13%
  Every day 33%
  Multiple times per day 16%
  Ever tried to stop using BZD 45%
Anxiety (GAD-7)
  Minimal (>4) 30%
  Mild (4–9) 33%
  Moderate (10–14) 21%
  Severe (≥15) 16%
Choice patterns
Would you enrol?
  Always ‘yes’ 49%
  Always ‘no’ 29%
  Average no of ‘yes’ (out of 6) 3.67
  Proportion of ‘yes’ (in all choice situations) 67%
Validity check
Would you like to be contacted if such 
programme started?
  ‘Yes’ in the full sample 45%
  ‘Yes’ among those who answered always 
‘no’ to the question ‘Would you enrol?’
15%
  ‘Yes’ among those who answered ‘yes’ 
at least once to the question ‘Would you 
enrol?’
57%
BZD, benzodiazepine; GAD-7, Generalized Anxiety Disorder 7-Item 
scale.
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exclude these as this does not necessarily reflect irra-
tional behaviour.
When heterogeneity in preferences is investigated 
using the latent class model (model 2), we identify two 
distinct classes (or types) of respondents. Class 1 respon-
dents have a high ASC, that is, a strong preference for 
opting-out—these individuals can be considered as 
‘non-traders’ as it is highly unlikely that they will enrol. 
We don’t observe any significant impact of programme 
attributes in this group. These respondents represent 
35.5% of the sample, which is in line with the observed 
rate of 30% in the choice patterns described above. 
Conversely, Class 2 respondents are responsive to all 
programme characteristics and are highly likely to choose 
to enrol. The attributes coefficients are of similar magni-
tude than in the conditional logit model. The latent class 
logit framework allows to model the likelihood of class 
membership as a function of individual characteristics. In 
other words, we model the probability for respondents 
to belong to the group of ‘non-traders’ (ie, class 1). We 
find that male and lower-income respondents were less 
likely to be non-traders (they are less likely to opt-out) 
and, perhaps not surprisingly, that respondents with a 
longer history of benzodiazepine use were more likely to 
opt-out. Figure 3 shows the predicted choices when the 
incentive amount for successful discontinuation is varied. 
The predicted enrolment rate among respondents was 
around 55.8% with an incentive of US$200 and reached 
74% when the incentive is set at US$2000.
dIsCussIOn
These results suggest that the enrolment rate among 
survey respondents for a behavioural economics trial 
encouraging benzodiazepine taper and discontinuation 
might range from 56% if the incentive for successful 
discontinuation was US$200 and up to 74% if the incen-
tive were US$2000. However, as only 28.4% of eligible 
patients agreed to participate and returned the survey, 
the real-world enrolment rate among eligible patients 
might be lower. The choice models indicate that all four 
studied programme characteristics (amount of cash 
incentive to start the programme, amount of incentive 
provided conditional on successful discontinuation, half 
of the incentive received if the dose is cut in half and 
incentive format) influenced the probability of choosing 
a given programme. The expectations regarding the 
design features of the incentive scheme were largely 
supported by the results. While higher incentives led to 
higher predicted uptake, the relationship was not linear, 
as found previously.24 We also found that respondents 
strongly favoured cash incentives rather than lotteries of 
equal expected value and that offering an incentive for 
reducing the dose by half is likely to increase enrolment. 
Further, willingness to participate was higher among men 
and low-income respondents and lower for respondents 
with a longer history of benzodiazepine use.
We conducted this choice experiment following best 
practice guidelines41 and within the population of interest, 
that is, older adults taking benzodiazepines. While our 
study offers valuable insight into the acceptability and 
potential take-up of incentive programmes for benzodi-
azepine discontinuation, it has several limitations. First, 
while stated preferences surveys have been widely used in 
health services research, it is important to keep in mind 
that we are analysing hypothetical choices and there-
fore our results should be interpreted with caution, as 
Figure 3 Predicted enrolment by incentive amount for successful discontinuation—Estimated choice probabilities obtained 
using model 2 in table 3.
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real-world decisions may differ, especially if the setting—
in particular features of the health system—differs widely 
from the US context. Nevertheless, DCEs have been shown 
to provide relatively accurate predictions of behaviour, 
with 80% agreement found between stated and revealed 
preferences.42 43 Also, beyond predicting choices, DCEs 
are helpful in understanding the relative importance 
of the various characteristics of the product or service 
under study. Second, we had an overall response rate of 
only 28.4%, which may reflect reluctance of people with 
long-term benzodiazepine use to discontinue.11 Third, as 
we opted for a paper-based survey, we cannot be certain 
that respondents did not receive support from friends 
or relatives to complete it. Finally, to keep the survey at 
a reasonable level of complexity and to reduce respon-
dent burden, we did not state other potentially relevant 
features of an incentive programme, such as programme 
length, contacts with providers or formal record of 
behavioural change.
This study is the first to provide insight into the 
acceptability of financial incentives for benzodiazepine 
discontinuation. Knowing that potential participants 
are sensitive to the incentive amount for initiating the 
programme and for successful completion, prefer certain 
versus lottery payment and prefer partial payment for 
dose reduction will be helpful in informing the design of 
future trials. Naturally, even if the intervention were effec-
tive in bringing about benzodiazepine discontinuation or 
dose reduction in a substantial number of participants, 
the long-term effects on health outcomes such as falls, 
automobile crashes, cognitive decline and quality of life 
would need to be demonstrated. Further, an economic 
evaluation of such a programme would be helpful to 
assess its financial viability and the potential return on 
investment/cost-effectiveness. In other words, from a 
health system perspective, are the benefits to patients in 
terms of avoided healthcare costs and improved health 
outcomes from discontinuing benzodiazepines large 
enough to justify a monetary investment? Recent research 
has shown that the health benefits (quality of life gained) 
of some types of drugs are likely to be offset by an increase 
in future costs, even when limiting the analysis to one cate-
gory of long-term costs (fall-related costs in this case).44 A 
comprehensive cost-effectiveness modelling study might 
help to better understand the potential returns of such 
investments, both in terms of avoided future costs and 
increase long-term quality of life.
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